JP6753861B2 - 慢性腎疾患の急速進行のバイオマーカー - Google Patents

慢性腎疾患の急速進行のバイオマーカー Download PDF

Info

Publication number
JP6753861B2
JP6753861B2 JP2017546035A JP2017546035A JP6753861B2 JP 6753861 B2 JP6753861 B2 JP 6753861B2 JP 2017546035 A JP2017546035 A JP 2017546035A JP 2017546035 A JP2017546035 A JP 2017546035A JP 6753861 B2 JP6753861 B2 JP 6753861B2
Authority
JP
Japan
Prior art keywords
expression
biomarker
antibody
biomarkers
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536558A (ja
JP2017536558A5 (enExample
Inventor
ブルエル，メラニー
ミュオラ，モルジ
テルジ，ファビオラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017536558A publication Critical patent/JP2017536558A/ja
Publication of JP2017536558A5 publication Critical patent/JP2017536558A5/ja
Application granted granted Critical
Publication of JP6753861B2 publication Critical patent/JP6753861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2017546035A 2014-11-25 2015-11-24 慢性腎疾患の急速進行のバイオマーカー Active JP6753861B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306879 2014-11-25
EP14306879.9 2014-11-25
PCT/EP2015/077504 WO2016083374A1 (en) 2014-11-25 2015-11-24 Biomarkers of fast progression of chronic kidney disease

Publications (3)

Publication Number Publication Date
JP2017536558A JP2017536558A (ja) 2017-12-07
JP2017536558A5 JP2017536558A5 (enExample) 2018-12-27
JP6753861B2 true JP6753861B2 (ja) 2020-09-09

Family

ID=52002880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546035A Active JP6753861B2 (ja) 2014-11-25 2015-11-24 慢性腎疾患の急速進行のバイオマーカー

Country Status (5)

Country Link
US (3) US20170328914A1 (enExample)
EP (1) EP3224625B1 (enExample)
JP (1) JP6753861B2 (enExample)
CN (1) CN107003320B (enExample)
WO (1) WO2016083374A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107003320B (zh) 2014-11-25 2021-08-17 豪夫迈·罗氏有限公司 慢性肾脏疾病的快速进展的生物标志物
US12057228B1 (en) 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
EP3665705B1 (en) * 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN112424608A (zh) * 2018-05-10 2021-02-26 卫理公会医院 用于疾病的预后和管理的方法
ES2745352B2 (es) * 2018-08-28 2023-08-10 Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz GDF15 en orina como biomarcador de enfermedad renal crónica
WO2020077267A1 (en) * 2018-10-11 2020-04-16 Northwestern University Biomarker of chronic kidney disease in liver transplant recipients
CN113667713A (zh) * 2020-05-14 2021-11-19 深圳市长卿医学研究院 一种肾功能损害风险降低的方法及应用
MX2023003379A (es) * 2020-09-23 2023-03-31 Baxter Int Sistema, metodos y aparato de prediccion de aprendizaje de maquina de enfermedad renal cronica (erc).
JP2024516548A (ja) * 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法
CN116042809B (zh) * 2022-12-12 2025-07-15 山西省人民医院 X连锁凋亡抑制蛋白在慢性肾脏病诊断中的应用
CN118707104A (zh) * 2024-05-08 2024-09-27 杭州珞米医疗科技有限公司 蛋白标志物联合用于制备诊断区分糖尿病肾病进展者与非进展者的试剂盒的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5438770B2 (ja) 2008-11-21 2014-03-12 ファディア・アクチボラグ 急性腎臓損傷を検出またはモニターするための方法、装置およびキット
JP5735922B2 (ja) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20130165344A1 (en) * 2010-06-23 2013-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2622095B1 (en) 2010-10-01 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
CN102854306B (zh) * 2011-12-23 2013-08-07 中国人民解放军第三〇九医院 用于预警肾移植后排斥反应的试剂盒及其使用方法
CN107003320B (zh) 2014-11-25 2021-08-17 豪夫迈·罗氏有限公司 慢性肾脏疾病的快速进展的生物标志物
WO2020077267A1 (en) 2018-10-11 2020-04-16 Northwestern University Biomarker of chronic kidney disease in liver transplant recipients

Also Published As

Publication number Publication date
US20200096523A1 (en) 2020-03-26
JP2017536558A (ja) 2017-12-07
US12203943B2 (en) 2025-01-21
EP3224625A1 (en) 2017-10-04
EP3224625B1 (en) 2020-07-29
CN107003320A (zh) 2017-08-01
WO2016083374A1 (en) 2016-06-02
US20220252617A1 (en) 2022-08-11
CN107003320B (zh) 2021-08-17
US20170328914A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
JP6753861B2 (ja) 慢性腎疾患の急速進行のバイオマーカー
CA3052349C (en) Proadm as marker indicating an adverse event
CN109716134B (zh) 败血症的检测
EP3497451B1 (en) Histones and/or proadm as markers indicating an adverse event
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
US20130252839A1 (en) Markers of primary graft dysfunction
JP2024150669A (ja) 子宮内膜症の診断方法、病態モニタリング方法及びキット
AU2014343709B2 (en) Biomarkers and methods for progression prediction for chronic kidney disease
AU2020343723A1 (en) Methods for confirming detection and evaluating the progression of a prostate cancer and related therapies
WO2015019979A1 (ja) 統合失調症に関するバイオマーカー
KR20210054506A (ko) 마커 검출용 키트 및 방법
HK1236242B (zh) 慢性肾脏疾病的快速进展的生物标志物
van der Ploeg et al. It takes two: Aberrant repair and low-grade inflammation characterizes bronchiolitis obliterans syndrome after lung transplantation in serum proteomic analysis
HK1236242A1 (en) Biomarkers of fast progression of chronic kidney disease
US20240118282A1 (en) Kits and methods for detecting markers and determining the presence or risk of cancer
CA3033102C (en) Histones and/or proadm as markers indicating organ dysfunction
JP2024160230A (ja) 小便サンプルを用いた腎臓疾患診断用組成物
HK40074056A (en) Diagnostic and prognostic methods for cardiovascular diseases and events

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200820

R150 Certificate of patent or registration of utility model

Ref document number: 6753861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250